Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.40 |
| ▸ | KIF11 | P52732 | 9/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12917528 | 0.90 | KIF11 (0.46) | KIF11 | |
| SCHEMBL17493273 | 0.87 | CA14 (0.41) | HDAC3HDAC1HDAC2NCOR2L3MBTL1 | |
| SCHEMBL26616743 | 0.84 | ACHE (0.43) | KIF11 | |
| SCHEMBL18291881 | 0.84 | CA14 (0.41) | HDAC3HDAC1HDAC2NCOR2L3MBTL1 | |
| SCHEMBL16141285 | 0.83 | CA14 (0.45) | HDAC3HDAC1HDAC2NCOR2L3MBTL1 | |
| SCHEMBL14708941 | 0.83 | CA14 (0.45) | HDAC3HDAC1HDAC2NCOR2L3MBTL1 | |
| SCHEMBL12917526 | 0.82 | CA14 (0.39) | HDAC3HDAC1HDAC2NCOR2L3MBTL1 | |
| SCHEMBL14709092 | 0.81 | CA14 (0.38) | HDAC3HDAC1HDAC2NCOR2L3MBTL1 | |
| SCHEMBL45876 | 0.80 | MEN1 (0.41) | HDAC3HDAC1HDAC2NCOR2L3MBTL1 | |
| SCHEMBL26616674 | 0.79 | ALDH1A1 (0.38) | HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120183616-A1 | LONG ACTING INSULIN COMPOSITION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120183616-A1 | LONG ACTING INSULIN COMPOSITION | IAPP, INSR, GPR119 | HDAC3 3334/4885HDAC1 3873/4885HDAC2 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.